Table 2 Viability of SP- and Non-SP cells treated with gefitinib and Kv channels blocker or Kv7 opener
Cell viability (%) | Gefitinib (2 μM) | TEA (5 mM) | 4-AP (2 mM) | Flupirtine (30 μM) | TEA (5 mM) | 4-AP (2 mM) | Flupirtine (30 μM) |
|---|---|---|---|---|---|---|---|
(Gef 2 μM) | |||||||
Non-SP | 59.68 (±4.54) | 79.09 (±5.62) | 72.46 (±5.45) | 58.08 (±5.67) | 20.39 (±3.27) | 20.54 (±5.22) | 32.02 (±3.48) |
SP | 105.32 (±10.92) | 84.22 (±4.40) | 83.32 (±5.43) | 63.00 (±8.81) | 23.84 (±4.27) | 27.44 (±8.87) | 30.63 (±3.95) |